SEC Form 4 filed by Chief Financial Officer Seelenberger Alexander A.
$VINC
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Vincerx Pharma, Inc. [ VINC ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 08/12/2024 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (right to buy) | $19 | 08/12/2024 | D(1) | 200,000 | (2) | 12/22/2030 | Common Stock | 200,000 | (1) | 0 | D | ||||
| Stock Option (right to buy) | $0.55 | 08/12/2024 | A(1) | 200,000 | (2) | 12/22/2030 | Common Stock | 200,000 | (1) | 200,000 | D | ||||
| Stock Option (right to buy) | $6.26 | 08/12/2024 | D(1) | 55,250 | (3) | 02/13/2032 | Common Stock | 55,250 | (1) | 0 | D | ||||
| Stock Option (right to buy) | $0.55 | 08/12/2024 | A(1) | 55,250 | (3) | 02/13/2032 | Common Stock | 55,250 | (1) | 55,250 | D | ||||
| Stock Option (right to buy) | $1.71 | 08/12/2024 | D(1) | 58,000 | (4) | 08/24/2032 | Common Stock | 58,000 | (1) | 0 | D | ||||
| Stock Option (right to buy) | $0.55 | 08/12/2024 | A(1) | 58,000 | (4) | 08/24/2032 | Common Stock | 58,000 | (1) | 58,000 | D | ||||
| Stock Option (right to buy) | $0.82 | 08/12/2024 | D(1) | 56,000 | (5) | 11/14/2032 | Common Stock | 56,000 | (1) | 0 | D | ||||
| Stock Option (right to buy) | $0.55 | 08/12/2024 | A(1) | 56,000 | (5) | 11/14/2032 | Common Stock | 56,000 | (1) | 56,000 | D | ||||
| Stock Option (right to buy) | $1.17 | 08/12/2024 | D(1) | 86,000 | (6) | 02/14/2033 | Common Stock | 86,000 | (1) | 0 | D | ||||
| Stock Option (right to buy) | $0.55 | 08/12/2024 | A(1) | 86,000 | (6) | 02/14/2033 | Common Stock | 86,000 | (1) | 86,000 | D | ||||
| Stock Option (right to buy) | $7.38 | 08/12/2024 | D(1) | 93,750 | (7) | 03/06/2034 | Common Stock | 93,750 | (1) | 0 | D | ||||
| Stock Option (right to buy) | $0.55 | 08/12/2024 | A(1) | 93,750 | (7) | 03/06/2034 | Common Stock | 93,750 | (1) | 93,750 | D | ||||
| Stock Option (right to buy) | $7.38 | 08/12/2024 | D(1) | 31,250 | (7) | 03/06/2034 | Common Stock | 31,250 | (1) | 0 | D | ||||
| Stock Option (right to buy) | $0.55 | 08/12/2024 | A(1) | 31,250 | (7) | 03/06/2034 | Common Stock | 31,250 | (1) | 125,000 | D | ||||
| Explanation of Responses: |
| 1. On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the "Repriced Options"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the "Repricing"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors. |
| 2. Option vests over two years, with 1/3 of the shares vesting on December 23, 2020, and 1/36th of the shares vesting monthly thereafter. |
| 3. Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter. |
| 4. Option vests in twenty-four equal monthly installments starting from August 25, 2022. |
| 5. Option vests in twenty-four equal monthly installments starting from November 15, 2022. |
| 6. Option vests in twenty-four equal monthly installments starting from February 15, 2023. |
| 7. One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter. |
| By: /s/ Alexander A. Seelenberger | 08/14/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||